The trial design was informed by results from our preclinical melanoma tumor model that showed enhanced tumor growth control, prolonged survival of mice and an increased IFN-γ response upon the combination of anti-PD-1 + anti-CTLA-4 with domatinostat. This evidence concerns the gene CTLA4 and neoplasm.